A Potential Solution for the 2022 Monkeypox Outbreak
Overview of Monkeypox
Monkeypox is a painful viral infection that has seen a significant rise in cases since April 2022. In response to this alarming increase, the World Health Organization declared the monkeypox outbreak a global health emergency in July 2022. Fortunately, advancements in science suggest that vaccinia-based vaccines may provide a crucial defense against this outbreak.
Understanding the Vaccinia-Based Vaccine
Vaccinia-based vaccines utilize inactivated or non-pathological viruses. These vaccines are being investigated for their potential use against monkeypox, drawing inspiration from their role in eradicating smallpox, a disease that claimed millions of lives. Recent studies indicate that these vaccines may effectively combat the monkeypox virus through a mechanism known as cross-reactivity.
Concept of Cross-Reactivity
Cross-reactivity refers to the similarities found within different viruses, which could lead to the development of immunity against multiple strains. Despite the genetic differences between the smallpox virus and the monkeypox virus, researchers are exploring whether vaccinia-based vaccines can still be effective.
To investigate this possibility, a team of researchers analyzed public databases to compare the genetic codes of the vaccinia virus from before the 1980s with the monkeypox viruses identified in 2022. Their focus was on the segments of the viruses that the immune system targets, known as epitopes. By comparing these epitopes, they aimed to assess the potential effectiveness of the vaccinia-based vaccine against the current monkeypox virus.
Findings on T Cell Epitopes
The researchers evaluated the genetic similarities among the epitopes recognized by T cells, which play a critical role in fighting infections. Their findings revealed significant similarities in these epitopes, suggesting a favorable association between the vaccinia-based vaccine and the activation of T cells.
Conclusion
The 2022 monkeypox virus shares many similar epitopes with the vaccinia virus, indicating that a vaccinia-based vaccine could serve as an effective defense against this strain of monkeypox. While these results are promising, further studies are necessary to understand the specificity of immune responses given the genetic variations between the two viruses.
References
1. Nuzzo JB, Borio LL, Gostin LO. The WHO Declaration of Monkeypox as a Global Public Health Emergency. JAMA. 2022;328(7):615–617. doi:10.1001/jama.2022.12513.
2. Ahmed SF, Sohail MS, Quadeer AA, Mckay MR. Vaccinia-Virus-Based Vaccines are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus. Viruses. 2022;14(9):1960. doi:10.3390/v14091960.
3. Navollotskaya EV. The Second Life of Antibodies. Biochemistry (Moscow). 2014; 79: 1-7. https://link.springer.com/article/10.1134/S0006297914010015.
4. Laidlaw BJ, Craft JE, Kaech SM. The Multifaceted Role of CD4(+) T Cells in CD8(+) T Cell Memory. Nat Rev Immunol. 2016;16(2):102-111. doi:10.1038/nri.2015.10.